Mesa Laboratories (MLAB) Given Daily News Impact Rating of 0.12

Media stories about Mesa Laboratories (NASDAQ:MLAB) have been trending somewhat positive on Wednesday, Accern Sentiment Analysis reports. Accern scores the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Mesa Laboratories earned a news sentiment score of 0.12 on Accern’s scale. Accern also gave media stories about the medical instruments supplier an impact score of 46.294798916599 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Mesa Laboratories (NASDAQ:MLAB) traded down $3.55 during trading hours on Wednesday, reaching $130.11. 12,400 shares of the company’s stock were exchanged, compared to its average volume of 15,160. The company has a current ratio of 2.86, a quick ratio of 1.97 and a debt-to-equity ratio of 0.48. The stock has a market cap of $491.78, a PE ratio of 46.97 and a beta of 0.42. Mesa Laboratories has a one year low of $113.57 and a one year high of $169.80.

Mesa Laboratories (NASDAQ:MLAB) last posted its quarterly earnings data on Monday, November 6th. The medical instruments supplier reported $0.60 earnings per share for the quarter, missing analysts’ consensus estimates of $0.64 by ($0.04). The firm had revenue of $22.95 million during the quarter, compared to analysts’ expectations of $25.50 million. Mesa Laboratories had a net margin of 11.48% and a return on equity of 14.77%. analysts predict that Mesa Laboratories will post 2.47 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 15th. Shareholders of record on Wednesday, February 28th will be given a $0.16 dividend. The ex-dividend date of this dividend is Tuesday, February 27th. This represents a $0.64 dividend on an annualized basis and a yield of 0.49%. Mesa Laboratories’s payout ratio is currently 23.10%.

A number of equities analysts have weighed in on the stock. TheStreet raised shares of Mesa Laboratories from a “c+” rating to a “b” rating in a research report on Monday, November 6th. Zacks Investment Research raised shares of Mesa Laboratories from a “strong sell” rating to a “buy” rating and set a $167.00 price objective for the company in a research report on Tuesday, October 3rd.

COPYRIGHT VIOLATION WARNING: This news story was posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The correct version of this news story can be read at

Mesa Laboratories Company Profile

Mesa Laboratories, Inc is focused primarily on quality control products and services. The Company operates through four segments: Instruments, Continuous Monitoring, Biological Indicators and Cold Chain. The Instruments Division designs, manufactures and markets quality control instruments and disposable products.

Insider Buying and Selling by Quarter for Mesa Laboratories (NASDAQ:MLAB)

Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit